Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements or mutant NPM1. Findings from the Phase I AUGMENT-101 trial were published today in Nature.
The overall response rate among 60 patients was 53%, and the rate of complete remission or complete...
Study discovers triple immunotherapy combination as possible treatment for pancreatic cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints...
Sotorasib shows clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer
In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety...
MD Anderson Research Highlights for December 19, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a cell cycle checkpoint inhibitor with potential therapeutic effects in an ovarian cancer subtype, a telementoring program for French-speaking oncology providers in Africa, insights into the relationship between obesity and immunotherapy...
Novel drug combinations and targeted therapies show promise for patients with leukemia
Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022...
MD Anderson Research Highlights: ASH 2022 Special Edition
ABSTRACTS 62, 82, 95, 199, 232, 540, 708, 766, 960
The University of Texas MD Anderson Cancer Center’s Research Highlights provides...
MD Anderson’s Christopher Flowers, M.D., receives ASH Mentor Award
Christopher Flowers, M.D., division head ad interim of Cancer Medicine and chair of Lymphoma & Myeloma at The University of Texas MD Anderson...
MD Anderson Research Highlights: SABCS 2022 Special Edition
ABSTRACTS GS1-07, GS5-08, PD6-11, HER2-01
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse...